Type 2 inflammation in chronic obstructive pulmonary disease: A promising treatable trait and practice recommendations Authors: Yan Chen, Ting Yang, Jing Zhang, Xiangqi Chen, Xin Chen, Zhe Cheng, Yaqing Li, Xiaoyun Fan, Wei Han, Zhiyi He, Dedong Ma, Ying Meng, Junxia Yan, Yan Yin, Huihui Zeng, Qiong Zhou, Xiaoming Zhou, Hui Cai, Yanan Cui, Yiming Ma, Fuqiang Wen, Yongchang Sun, Dejun Sun, Xiaoju Liu, Jinping Zheng, Wei Wang, Zeguang Zheng, Xixin Yan, Shaoxi Cai, Jie Cao, Yuanlin Song, Jianping Zhao, Yumin Zhou, Huili Zhu, Manxiang Li, Yanfei Guo, Qianli Ma, Zhenyu Liang, Li Zhao, Yahong Chen Published: 2025 ABSTRACT BackgroundType 2 inflammation is a key inflammatory endotype of chronic obstructive pulmonary disease (COPD). The precise identification and targeted intervention of treatable traits related to type 2 inflammation are crucial directions in the current management of COPD. Recently, a growing body of evidence-based medical data has accumulated regarding the clinical characteristics, biomarkers, therapeutic agents, and efficacy evaluation of type 2 inflammation in COPD, providing strong support for clinical diagnosis and treatment. This clinical practice recommendation systematically reviewed the evidence-based medical literature and integrated clinical experience to present expert opinions, aiming to standardize and improve the management of type 2 inflammation in COPD.MethodsThis clinical practice recommendation followed Appraisal of Guidelines for Research and Evaluation II (AGREE II) and the Reporting Items for Practice Guidelines in HealThcare (RIGHT) statement to ensure the thoroughness and transparency. Clinical questions were primarily derived from surveys among experts in the field and thorough discussion at meetings. The evidence grading levels and recommendation grades adopted in the clinical practice recommendation follow the evidence grading levels and recommendation grades established by the Oxford Centre for Evidence-Based Medicine. The expert opinions were formulated through open discussion and expert voting. Expert opinions with an agreement rate of 80 % or higher among the experts are incorporated in the clinical practice recommendation.ResultsEight clinical questions concerning diagnosis and treatment were proposed after expert discussion. In addition, fifteen specific major points of expert opinions about type 2 inflammation in COPD, involving clinical features, biomarkers, correlation with clinical outcomes, inhaled corticosteroid (ICS) treatment, biologic treatment and treatment response, were determined.ConclusionsA set of comprehensive clinical practice recommendations focusing on the treatable trait of type 2 inflammation in COPD was established, which may provide potential guidance for the precision management of COPD. Introduction Chronic obstructive pulmonary disease (COPD), as a major global public health issue, poses a serious threat to human health and quality of life.1 Based on the predominant immune cells and cytokines involved, airway inflammation in COPD is categorized into type 1 inflammation, type 2 inflammation, and type 3 inflammation, among which type 1 and type 3 are usually grouped as non-type 2 inflammation.2,3 It was previously believed that type 1 and type 3 inflammation played a dominant role in the vast majority of COPD patients.4 However, the meta-analysis suggests that when using a blood eosinophil (EOS) threshold of ≥2 %, the proportion of COPD patients with concurrent type 2 inflammation ranges from 9.58 % to 66.88 %.5 Type 2 inflammation not only participates in pathological processes such as airway remodeling and mucus hypersecretion,6 but also closely associates with the risk of acute exacerbations and decline in lung function.7,8 Some scholars have proposed that type 2 inflammation can serve as a key treatable trait, holding great potential for guiding individualized and precision treatment of COPD.4,9 The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2025 has recommended using blood EOS count as a biomarker to identify the type 2 inflammatory endotype and/or predict response to inhaled corticosteroids (ICS) and biologics.10 To standardize and optimize the clinical diagnosis and treatment practices for treatable traits of type 2 inflammation in COPD, practice recommendations have been formulated based on the latest research evidence and clinical expert experience, aiming to provide clinicians with a scientific and practical guidance framework and to promote the advancement of precision diagnosis and treatment of COPD. Audience for the clinical practice recommendations The clinical practice recommendations are intended for physicians and nursing professionals engaged in the clinical practice of COPD. Contents and update plan The contents mainly involve three parts: assessment of inflammatory endotype in COPD, recognition and assessment of type 2 inflammation in COPD, and therapeutic strategies for COPD patients with type 2 inflammation, amounting to eight clinical questions and fifteen major points of expert opinions. Summary and strengths of the expert recommendations are demonstrated in Table 1. The clinical practice recommendations are intended to be updated in 2027.Table 1Summary and strengths of the expert opinions.Table 1:No.Clinical questions and recommendationsStrength of recommendationsPart I. Assessment of inflammatory endotype in COPD1How important is the assessment of inflammatory endotypes in COPD?1.1All COPD patients should undergo assessment of inflammatory endotypes to guide individualized precision management.Evidence level 2a; recommendation strength BPart II. Recognition and assessment of type 2 inflammation in COPD2Which clinical features help identify type 2 inflammation in COPD?2.1COPD patients presenting with asthma-like features should be considered as having concomitant type 2 inflammation.Evidence level 2b; recommendation strength B2.2A history of childhood asthma, allergen exposure, and a family history of asthma are susceptibility factors for COPD patients with type 2 inflammation.Evidence level 2b; recommendation strength B2.3For COPD patients, active assessment of the coexistence of type 2 inflammatory diseases (such as asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, etc.) is recommended.Evidence level 2b; recommendation strength B2.4COPD patients with type 2 inflammation are more sensitive to corticosteroid treatment compared to those without type 2 inflammation.Evidence level 1a; recommendation strength A3Which biomarkers can be used for the clinical assessment of type 2 inflammation in COPD patients?3.1As a biomarker for the clinical assessment of type 2 inflammation in COPD patients, a blood EOS count ≥300 cells/µL and/or sputum EOS count ≥3 % can identify characteristics of type 2 inflammation.Evidence level 2b; recommendation strength B3.2FeNO is a potential biomarker for the clinical assessment of type 2 inflammation in COPD. A FeNO50 ≥20 ppb, in combination with other biomarkers, can assist in identifying features of type 2 inflammation.Evidence level 2b; recommendation strength B3.3IgE may serve as one of the potential biomarkers for the clinical assessment of type 2 inflammation in COPD patients.Evidence level 2b; recommendation strength B4What is the correlation between type 2 inflammation and clinical outcomes in COPD patients?4.1COPD patients with type 2 inflammation have an increased risk of acute exacerbations and hospitalizations, faster lung function decline, and more severe respiratory symptoms. Therefore, more importance should be attached to the monitoring and follow-up of patients with type 2 inflammation.Evidence level 2b; recommendation strength BPart III. Therapeutic intervention to COPD patients with type 2 inflammation5How effective are ICS in treating COPD with type 2 inflammation?5.1For stable COPD patients with characteristics of type 2 inflammation, ICS should be considered in combination with long-acting bronchodilators.Evidence level 1a; recommendation strength A6What are the therapeutic strategies for biologics targeting type 2 inflammation in COPD?6.1For COPD patients with type 2 inflammation who continue to experience acute exacerbations despite optimized inhalation therapy, it is recommended to add biologic agents.Evidence level 1b; recommendation strength A7How should the therapeutic response to biologics be assessed in COPD patients with type 2 inflammation?7.1After initiating biologic therapy in COPD patients with type 2 inflammation, symptoms, lung function, and the occurrence of acute exacerbations should be dynamically assessed.Evidence level 1b; recommendation strength A7.2For COPD patients with type 2 inflammation, it is not recommended to evaluate the therapeutic response to biologics solely based on changes in blood EOS counts.Evidence level 1b; recommendation strength A7.3For COPD patients with type 2 inflammation, adverse reactions related to the biologic agents should be monitored during treatment.Evidence level 5; recommendation strength D8How should biologic treatment be provided for patients with COPD and type 2 inflammation who also have comorbid conditions?8.1For COPD patients with type 2 inflammation accompanied by other type 2 inflammatory diseases such as asthma or atopic dermatitis, it is recommended to initiate biologic therapy in accordance with relevant clinical guidelines.Evidence level 4; recommendation strength CCOPD: Chronic obstructive pulmonary disease; EOS: Eosinophils; FeNO: Fractional exhaled nitric oxide; FeNO50: Fractional exhaled nitric oxide at 50 mL/s; ICS: Inhaled corticosteroids; IgE: Immunoglobulin E; IL: Interleukin. Table 1Summary and strengths of the expert opinions.Table 1:No.Clinical questions and recommendationsStrength of recommendationsPart I. Assessment of inflammatory endotype in COPD1How important is the assessment of inflammatory endotypes in COPD?1.1All COPD patients should undergo assessment of inflammatory endotypes to guide individualized precision management.Evidence level 2a; recommendation strength BPart II. Recognition and assessment of type 2 inflammation in COPD2Which clinical features help identify type 2 inflammation in COPD?2.1COPD patients presenting with asthma-like features should be considered as having concomitant type 2 inflammation.Evidence level 2b; recommendation strength B2.2A history of childhood asthma, allergen exposure, and a family history of asthma are susceptibility factors for COPD patients with type 2 inflammation.Evidence level 2b; recommendation strength B2.3For COPD patients, active assessment of the coexistence of type 2 inflammatory diseases (such as asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, etc.) is recommended.Evidence level 2b; recommendation strength B2.4COPD patients with type 2 inflammation are more sensitive to corticosteroid treatment compared to those without type 2 inflammation.Evidence level 1a; recommendation strength A3Which biomarkers can be used for the clinical assessment of type 2 inflammation in COPD patients?3.1As a biomarker for the clinical assessment of type 2 inflammation in COPD patients, a blood EOS count ≥300 cells/µL and/or sputum EOS count ≥3 % can identify characteristics of type 2 inflammation.Evidence level 2b; recommendation strength B3.2FeNO is a potential biomarker for the clinical assessment of type 2 inflammation in COPD. A FeNO50 ≥20 ppb, in combination with other biomarkers, can assist in identifying features of type 2 inflammation.Evidence level 2b; recommendation strength B3.3IgE may serve as one of the potential biomarkers for the clinical assessment of type 2 inflammation in COPD patients.Evidence level 2b; recommendation strength B4What is the correlation between type 2 inflammation and clinical outcomes in COPD patients?4.1COPD patients with type 2 inflammation have an increased risk of acute exacerbations and hospitalizations, faster lung function decline, and more severe respiratory symptoms. Therefore, more importance should be attached to the monitoring and follow-up of patients with type 2 inflammation.Evidence level 2b; recommendation strength BPart III. Therapeutic intervention to COPD patients with type 2 inflammation5How effective are ICS in treating COPD with type 2 inflammation?5.1For stable COPD patients with characteristics of type 2 inflammation, ICS should be considered in combination with long-acting bronchodilators.Evidence level 1a; recommendation strength A6What are the therapeutic strategies for biologics targeting type 2 inflammation in COPD?6.1For COPD patients with type 2 inflammation who continue to experience acute exacerbations despite optimized inhalation therapy, it is recommended to add biologic agents.Evidence level 1b; recommendation strength A7How should the therapeutic response to biologics be assessed in COPD patients with type 2 inflammation?7.1After initiating biologic therapy in COPD patients with type 2 inflammation, symptoms, lung function, and the occurrence of acute exacerbations should be dynamically assessed.Evidence level 1b; recommendation strength A7.2For COPD patients with type 2 inflammation, it is not recommended to evaluate the therapeutic response to biologics solely based on changes in blood EOS counts.Evidence level 1b; recommendation strength A7.3For COPD patients with type 2 inflammation, adverse reactions related to the biologic agents should be monitored during treatment.Evidence level 5; recommendation strength D8How should biologic treatment be provided for patients with COPD and type 2 inflammation who also have comorbid conditions?8.1For COPD patients with type 2 inflammation accompanied by other type 2 inflammatory diseases such as asthma or atopic dermatitis, it is recommended to initiate biologic therapy in accordance with relevant clinical guidelines.Evidence level 4; recommendation strength CCOPD: Chronic obstructive pulmonary disease; EOS: Eosinophils; FeNO: Fractional exhaled nitric oxide; FeNO50: Fractional exhaled nitric oxide at 50 mL/s; ICS: Inhaled corticosteroids; IgE: Immunoglobulin E; IL: Interleukin. Summary and strengths of the expert opinions. COPD: Chronic obstructive pulmonary disease; EOS: Eosinophils; FeNO: Fractional exhaled nitric oxide; FeNO50: Fractional exhaled nitric oxide at 50 mL/s; ICS: Inhaled corticosteroids; IgE: Immunoglobulin E; IL: Interleukin. Methods Clinical practice recommendation development group The practice recommendations were jointly initiated by Assembly of COPD of Chinese Thoracic Society (CTS), COPD working group of Chinese Association of Chest Physician (CACP) of the Chinese Medical Doctor Association, Evidence-Based Medicine Group of the Clinical Epidemiology Branch of the Chinese Medical Association, Respiratory Disease Control Committee of the Chinese Preventive Medicine Association, and Precision Medicine Group of the Respiratory Disease Committee of the Cross-Strait Medical and Health Exchange Association. The clinical practice recommendation development group comprised thirty-six experts on respiratory medicine, allergic medicine, airway inflammation mechanism, and methodology across China. All participants involved in the development of this practice recommendation declared no conflicts of interest. Development of clinical practice recommendations We referenced Appraisal of Guidelines for Research and Evaluation II (AGREE II) and followed the Reporting Items for practice Guidelines in HealThcare (RIGHT) statement before and during development of the practice recommendations to ensure quality.11,12 Practice recommendations are based on evidence related to the clinical diagnosis and treatment of type 2 inflammation in COPD patients, and adopt the 2009 version of the Oxford Centre for Evidence-Based Medicine Levels of Evidence and Strength of Recommendations (Table 2).13 It has been registered bilingually on the International Practice Guidelines Registry and Transparency Platform (http://www.guidelines-registry.cn) with the registration number of PREPARE-2024CN915.Table 2Oxford centre for evidence-based medicine levels of evidence and grades of recommendation.Table 2:Strength of recommendationLevel of evidenceType of studyA1aSystematic review of homogeneous RCTs1bIndividual RCT [narrow confidence interval]1c“All or none” case-seriesB2aSystematic review of homogeneous cohort studies2bIndividual cohort study (including low-quality RCTs, e.g., follow-up rate <80 %)2cOutcomes research or ecological studies3aSystematic review of homogeneous case-control studies3bIndividual case-control studyC4Case series (including low-quality cohort or case-control studies)D5Expert opinion (i.e., without supporting clinical studies, based solely on basic research or clinical experience-based speculation)RCT: Randomized controlled trial. Table 2Oxford centre for evidence-based medicine levels of evidence and grades of recommendation.Table 2:Strength of recommendationLevel of evidenceType of studyA1aSystematic review of homogeneous RCTs1bIndividual RCT [narrow confidence interval]1c“All or none” case-seriesB2aSystematic review of homogeneous cohort studies2bIndividual cohort study (including low-quality RCTs, e.g., follow-up rate <80 %)2cOutcomes research or ecological studies3aSystematic review of homogeneous case-control studies3bIndividual case-control studyC4Case series (including low-quality cohort or case-control studies)D5Expert opinion (i.e., without supporting clinical studies, based solely on basic research or clinical experience-based speculation)RCT: Randomized controlled trial. Oxford centre for evidence-based medicine levels of evidence and grades of recommendation. RCT: Randomized controlled trial. Clinical questions were primarily derived from surveys among experts, and eight clinical questions were determined by comprehensive discussion at meetings. Whenever possible, the clinical questions were structured in the PICO format (Population, Intervention, Comparison, and Outcome). Following a review of the evidence pertaining to each clinical question, consensus was achieved through an open discussion coupled with a voting process. During this process, a threshold of 80 % was established as the criterion for approving a recommendation. The strengths of the recommendations were categorized as A, B, C, and D according to the criteria in Table 2. The clinical practice recommendations underwent a thorough review by external experts who had no direct involvement in their development. Their feedback was diligently gathered and, where applicable, integrated into the report. Evidence synthesis A comprehensive search was conducted across databases including PubMed, EMBASE, Wanfang Database, and China National Knowledge Infrastructure Database, covering from 2005 to 2025, with no restrictions concerning date or language. As outlined in Table 2, the quality of the evidence was assessed utilizing the standard “Oxford Centre for Evidence-Based Medicine Levels of Evidence”. Recommendations and evidence profiles Part I. Assessment of inflammatory endotype in COPD Clinical question 1: How important is the assessment of inflammatory endotypes in COPD?Recommendation 1.1: All COPD patients should undergo assessment of inflammatory endotypes to guide individualized precision management (evidence level 2a; recommendation strength B; 30 voting experts, approval rate 100 %). Clinical question 1: How important is the assessment of inflammatory endotypes in COPD? Clinical question 1: How important is the assessment of inflammatory endotypes in COPD? Recommendation 1.1: All COPD patients should undergo assessment of inflammatory endotypes to guide individualized precision management (evidence level 2a; recommendation strength B; 30 voting experts, approval rate 100 %). Recommendation 1.1: All COPD patients should undergo assessment of inflammatory endotypes to guide individualized precision management (evidence level 2a; recommendation strength B; 30 voting experts, approval rate 100 %). COPD is a heterogeneous lung disease characterized by chronic respiratory symptoms and persistent, progressively worsening airflow limitation caused by abnormalities in the airways and/or alveoli.10 The development and progression of COPD are generally associated with various forms of chronic airway inflammation. The inflammatory drivers differ among patients, exhibiting heterogeneity, which poses significant challenges to comprehensive disease management. 14 Inflammatory endotypes of COPD With the advancement of research on the inflammatory mechanisms of COPD, the concept of “inflammatory endotypes” has been proposed in recent years. This classification reflects the essential inflammatory nature of COPD at the level of pathogenesis and guides precision treatment of COPD through reliable endotype biomarkers.15 Table 3 illustrated the key immune cells and cytokines of different inflammatory endotypes in COPD. Type 1/3 inflammation is typically defined as an immune response driven by the activation of T helper 1 cells (Th1), T helper 17 cells (Th17), natural killer cells (NK), group 1 innate lymphoid cells (ILC1), and group 3 innate lymphoid cells (ILC3). Type 2 inflammatory response is characterized by the production of type 2 cytokines, including interleukin (IL)-4, IL-5, and IL-13. These cytokines are secreted by T helper 2 cells (Th2) and group 2 innate lymphoid cells (ILC2) under the influence of epithelial-derived alarmins such as IL-25, IL-33 and thymic stromal lymphopoietin (TSLP). Additionally, infiltration of EOS, mast cells, and basophils, as well as selective activation of macrophages, are also important features of type 2 inflammation.4,16 Persistent activation of type 2 inflammation in airway tissues promotes pathophysiological changes associated with COPD.17,18 Mechanisms of type 2 inflammation in COPD are demonstrated in Fig. 1.Table 3The key immune cells and cytokines of different inflammatory endotypes in COPD.4,16,176Table 3:ItemsType 1 inflammationType 2 inflammationType 3 inflammationImmune cellsTh1, ILC1, macrophages, NKTh2, ILC2, mast cells, Tfh, basophils, EOSTh17, ILC3, Th22, neutrophilsKey cytokinesTNF-α, IFN-γ, IL-6, IL-12, IL-18, IL-2IL-4, IL-5, IL-13, IL-31IL-6, IL-17, IL-22, IL-23COPD: Chronic obstructive pulmonary disease; EOS: Eosinophils; IFN: Interferon; IL: Interleukin; ILC: Innate lymphoid cells; NK: Natural killer cells; Tfh: T follicular helper cells; Th: T helper cells; TNF: Tumor necrosis factor.Fig. 1Mechanisms of type 2 inflammation in COPD.177,178 COPD: Chronic obstructive pulmonary disease; IgE: Immunoglobulin E; IL: Interleukin; ILC: Innate lymphoid cells; Th: T helper cells; TSLP: Thymic stromal lymphopoietin.Fig. 1 Table 3The key immune cells and cytokines of different inflammatory endotypes in COPD.4,16,176Table 3:ItemsType 1 inflammationType 2 inflammationType 3 inflammationImmune cellsTh1, ILC1, macrophages, NKTh2, ILC2, mast cells, Tfh, basophils, EOSTh17, ILC3, Th22, neutrophilsKey cytokinesTNF-α, IFN-γ, IL-6, IL-12, IL-18, IL-2IL-4, IL-5, IL-13, IL-31IL-6, IL-17, IL-22, IL-23COPD: Chronic obstructive pulmonary disease; EOS: Eosinophils; IFN: Interferon; IL: Interleukin; ILC: Innate lymphoid cells; NK: Natural killer cells; Tfh: T follicular helper cells; Th: T helper cells; TNF: Tumor necrosis factor. The key immune cells and cytokines of different inflammatory endotypes in COPD.4,16,176 COPD: Chronic obstructive pulmonary disease; EOS: Eosinophils; IFN: Interferon; IL: Interleukin; ILC: Innate lymphoid cells; NK: Natural killer cells; Tfh: T follicular helper cells; Th: T helper cells; TNF: Tumor necrosis factor. Mechanisms of type 2 inflammation in COPD.177,178 COPD: Chronic obstructive pulmonary disease; IgE: Immunoglobulin E; IL: Interleukin; ILC: Innate lymphoid cells; Th: T helper cells; TSLP: Thymic stromal lymphopoietin. Role of type 2 inflammation in COPD In patients with COPD, exposure to risk factors such as cigarette smoke, microbial infections, and oxidative stress can induce airway epithelial cell damage and the release of epithelial-derived alarmins (such as IL-25, IL-33, and TSLP). These alarmins further activate ILC2, Th2 cells, and other immune cells, promoting the release of type 2 cytokines and inducing type 2 inflammatory responses.19 Among these alarmins, IL-33 currently has the most robust mechanistic evidence base. Loss-of-function mutations in the IL33 gene are associated with a reduced risk of developing COPD.20 As a member of the interleukin-1 (IL-1) family, IL-33 binds to its transmembrane receptor—suppression of tumorigenicity 2 protein (ST2)—to recruit and activate innate and adaptive immune cells.21 In type 2 inflammation, IL-33 promotes the differentiation of T lymphocytes into Th2 cells via dendritic cells (DCs), and induces ILC2 to produce IL-4, IL-5, and IL-13.22 Another epithelial-derived alarmin, TSLP, is an IL-7-like cytokine that binds to a heterodimeric receptor complex composed of interleukin-7 receptor alpha (IL-7Rα) and the TSLP receptor. Its main function is to promote Th2 cell expansion and induce Th2 cells, mast cells, and natural killer cells to produce type 2 cytokines such as IL-4 and IL-5.23 Additionally, TSLP activates DCs into CD11c⁺ DCs, which produce type 2 chemokines, induce naive CD4⁺ T cell proliferation, and promote the expression of IL-4, IL-5, IL-13, and TNF-α, while suppressing IL-10 and interferon-gamma (IFN-γ) expression, thereby creating a type 2 inflammation-polarized microenvironment.24 Type 2 cytokines, represented by IL-4, IL-13, and IL-5, play a central role in the initiation of type 2 inflammation.25 In type 2 inflammation, IL-4 is secreted by activated Th2 cells and ILC2s, and induces the differentiation of Th0 cells into Th2 cells via a positive feedback mechanism. In addition, IL-4 upregulates the expression of vascular cell adhesion molecule-1 (VCAM-1) on the endothelial surface, promoting the adhesion of EOS to the pulmonary vascular endothelium and their migration into lung tissue.26 IL-13 shares the IL-4 receptor α subunit (IL-4Rα) with IL-4 and therefore has overlapping functions, such as inducing epithelial cells to produce EOS chemotactic factors (EOS activation chemokines).27 However, IL-13 mainly mediates goblet cell metaplasia and mucin secretion in airway epithelial cells through the signal transducer and activator of transcription 6 (STAT6) signaling pathway.28 Additionally, IL-13 modulates the sensitivity of airway smooth muscle cells to calmodulin, disrupts tight junctions in the airway epithelium, and induces fibroblast proliferation, thereby promoting airway contraction and remodeling.27 Moreover, IL-4 and IL-13 synergistically promote B cell class switching, immunoglobulin E (IgE) production, degranulation of mast cells and basophils, and polarization of M2 macrophages.29 The release of IL-5 is strongly correlated to eosinophilia by acting mainly on cells of eosinophilic origin, wherein it stimulates their growth and differentiation, enhances their survival and promotes the release of their granular contents at the site of inflammation. Additionally, IL-5 exerts its effects on target cells through interaction with the IL-5 receptor (IL-5R).30 EOS activation is a key downstream effector in type 2 inflammation related to COPD. EOSs are produced in the bone marrow from multipotent hematopoietic stem cells and regulated by cytokines such as IL-3, IL-5, and granulocyte-macrophage colony-stimulating factor. Under the combined influence of type 2 cytokines and eosinophil chemoattractants, EOSs migrate through the bloodstream to lung tissues. Once in the lungs, EOSs release inflammatory mediators through degranulation, including peroxidase, major basic protein, EOSs cationic protein, and leukotrienes, thereby exacerbating airway epithelial injury and inflammation. In addition to their direct inflammatory effects, EOSs also release IL-13, which induces mucin 5 subtype AC (MUC5AC) expression, leading to excessive airway mucus secretion. Moreover, EOSs secrete transforming growth factor-beta (TGF-β), promoting fibroblast proliferation and collagen deposition, contributing to airway wall thickening and remodeling.6 Part II. Recognition and assessment of type 2 inflammation in COPD Clinical question 2: Which clinical features help identify type 2 inflammation in COPD?Recommendation 2.1: COPD patients presenting with asthma-like features should be considered as having concomitant type 2 inflammation (evidence level 2b; recommendation strength B; 30 voting experts, approval rate 100 %).Recommendation 2.2: A history of childhood asthma, allergen exposure, and a family history of asthma are susceptibility factors for COPD patients with type 2 inflammation (evidence level 2b; recommendation strength B; 30 voting experts, approval rate 100 %).Recommendation 2.3: For COPD patients, active assessment of the coexistence of type 2 inflammatory diseases (such as asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, etc.) is recommended (evidence level 2b; recommendation strength B; 30 voting experts, approval rate 100 %).Recommendation 2.4: COPD patients with type 2 inflammation are more sensitive to corticosteroid treatment compared to those without type 2 inflammation (evidence level 1a; recommendation strength A; 30 voting experts, approval rate 100 %). Clinical question 2: Which clinical features help identify type 2 inflammation in COPD? Clinical question 2: Which clinical features help identify type 2 inflammation in COPD? Recommendation 2.1: COPD patients presenting with asthma-like features should be considered as having concomitant type 2 inflammation (evidence level 2b; recommendation strength B; 30 voting experts, approval rate 100 %). Recommendation 2.1: COPD patients presenting with asthma-like features should be considered as having concomitant type 2 inflammation (evidence level 2b; recommendation strength B; 30 voting experts, approval rate 100 %). Recommendation 2.2: A history of childhood asthma, allergen exposure, and a family history of asthma are susceptibility factors for COPD patients with type 2 inflammation (evidence level 2b; recommendation strength B; 30 voting experts, approval rate 100 %). Recommendation 2.2: A history of childhood asthma, allergen exposure, and a family history of asthma are susceptibility factors for COPD patients with type 2 inflammation (evidence level 2b; recommendation strength B; 30 voting experts, approval rate 100 %). Recommendation 2.3: For COPD patients, active assessment of the coexistence of type 2 inflammatory diseases (such as asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, etc.) is recommended (evidence level 2b; recommendation strength B; 30 voting experts, approval rate 100 %). Recommendation 2.3: For COPD patients, active assessment of the coexistence of type 2 inflammatory diseases (such as asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, etc.) is recommended (evidence level 2b; recommendation strength B; 30 voting experts, approval rate 100 %). Recommendation 2.4: COPD patients with type 2 inflammation are more sensitive to corticosteroid treatment compared to those without type 2 inflammation (evidence level 1a; recommendation strength A; 30 voting experts, approval rate 100 %). Recommendation 2.4: COPD patients with type 2 inflammation are more sensitive to corticosteroid treatment compared to those without type 2 inflammation (evidence level 1a; recommendation strength A; 30 voting experts, approval rate 100 %). Clinical manifestations A detailed evaluation of the clinical manifestations of COPD patients should be conducted. Asthma-like features and/or airway hyperresponsiveness can provide valuable clues for identifying type 2 inflammation. Asthma-like features include: onset of symptoms before the age of 40, worsening of symptoms at night or early morning, symptoms triggered by exercise, emotional changes, dust, or allergens, seasonal variation of symptoms, spontaneous symptom remission, significant symptom improvement after using ICS, positive bronchodilator test (improvement of forced expiratory volume in 1 s [FEV1] ≥12 % and an absolute increase ≥200 mL after inhaling bronchodilator), elevated blood eosinophils (baseline blood eosinophil count ≥300 cells/µL), and positive specific IgE test to any inhaled antigen.31,32 When COPD patients present asthma-like features, the coexistence of type 2 inflammatory phenotype should be considered.31, 32, 33 Airway hyperresponsiveness (AHR) refers to the exaggerated contraction response of the airways to various physical, chemical, or biological stimuli, resulting in a significant increase in airway resistance and thereby causing or worsening symptoms such as dyspnea, wheezing, and cough.34 AHR is considered a hallmark feature of asthma and can be quantified and assessed through bronchial provocation tests; however, some COPD patients, especially those with asthma-like features, may also exhibit AHR.34,35 Patients with AHR typically show more pronounced airway inflammation, poorer lung function, and more frequent acute exacerbations, although systemic inflammatory marker levels may be normal or even decreased.35,36 These findings suggest that for COPD patients with AHR, close attention should be paid to the possibility of concomitant type 2 inflammation. Medical history characteristics Detailed medical history collection is crucial for identifying type 2 inflammation in COPD patients, including childhood asthma, allergen exposure, and a family history of asthma. Childhood asthma history A history of childhood asthma is considered an important risk factor for COPD. Early-life respiratory diseases, including asthma, affect lifelong lung function trajectories.37 Patients with childhood asthma have a significantly increased risk of developing COPD, often presenting as an overlap of asthma and COPD with type 2 inflammation as a typical feature.38, 39, 40 It is noteworthy that patients who had severe asthma during childhood are more likely to develop COPD in adulthood.41 Allergen exposure Allergen exposure is not only an important characteristic of asthma but is also common in COPD patients. Common allergens include fungi, dust mites, and pets.42,43 Allergen exposure plays a crucial role in the atopic development of COPD patients.42 Whether indoors or outdoors, a large number of allergens in the living environment are associated with more severe symptoms, impaired lung function, and frequent acute exacerbations.43 In mouse models, dual exposure to allergens and cigarette smoke leads to eosinophilic airway inflammation, airway remodeling, and AHR.44 This indicates that allergen exposure is one of the key factors driving type 2 inflammation. Family history of asthma Family history is another important factor in identifying type 2 inflammation in COPD. It has been confirmed that, regardless of smoking status, a family history of asthma is an independent risk factor for both COPD and asthma-COPD overlap (ACO).45,46 Comorbidities A detailed assessment of comorbidities in COPD patients is essential. Studies have shown that blood EOS levels are positively correlated with the incidence of type 2 inflammatory comorbidities in COPD. About >40 % of COPD patients have one to three additional EOS-associated diseases, including: asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, non-cystic fibrosis bronchiectasis, chronic spontaneous urticaria, eosinophilic esophagitis, bullous pemphigoid, allergic bronchopulmonary aspergillosis, eosinophilic granulomatosis with polyangiitis, and eosinophilic gastritis/gastroenteritis.47 Response to treatment A detailed evaluation of ICS treatment responsiveness in COPD patients is essential. COPD patients with type 2 inflammation are generally more sensitive to ICS therapy. Among COPD patients with a history of acute exacerbations, those with high blood EOS levels respond better to ICS treatment than those with low blood EOS levels, especially in reducing acute exacerbations.6,48, 49, 50, 51, 52, 53, 54 Other studies have found that withdrawal of ICS in triple therapy leads to more frequent acute exacerbations in patients with high blood EOS levels.55,56 On the other hand, COPD patients with elevated sputum EOS counts or fractional exhaled nitric oxide (FeNO) levels show more significant improvement in lung function after ICS treatment.57, 58, 59, 60, 61 These findings suggest that ICS-dependent COPD may be primarily driven by type 2 inflammation.Clinical question 3: Which biomarkers can be used for the clinical assessment of type 2 inflammation in COPD patients?Recommendation 3.1: As a biomarker for the clinical assessment of type 2 inflammation in COPD patients, a blood EOS count ≥300 cells/µL and/or sputum EOS count ≥3 % can identify characteristics of type 2 inflammation (evidence level 2b; recommendation strength B; 30 voting experts, approval rate 100 %).Recommendation 3.2: FeNO is a potential biomarker for the clinical assessment of type 2 inflammation in COPD. A FeNO50 ≥20 ppb, in combination with other biomarkers, can assist in identifying features of type 2 inflammation (evidence level 2b; recommendation strength B; 30 voting experts, approval rate 100 %).Recommendation 3.3: IgE may serve as one of the potential biomarkers for the clinical assessment of type 2 inflammation in COPD patients (evidence level 2b; recommendation strength B; 30 voting experts, approval rate 100 %). Clinical question 3: Which biomarkers can be used for the clinical assessment of type 2 inflammation in COPD patients? Clinical question 3: Which biomarkers can be used for the clinical assessment of type 2 inflammation in COPD patients? Recommendation 3.1: As a biomarker for the clinical assessment of type 2 inflammation in COPD patients, a blood EOS count ≥300 cells/µL and/or sputum EOS count ≥3 % can identify characteristics of type 2 inflammation (evidence level 2b; recommendation strength B; 30 voting experts, approval rate 100 %). Recommendation 3.1: As a biomarker for the clinical assessment of type 2 inflammation in COPD patients, a blood EOS count ≥300 cells/µL and/or sputum EOS count ≥3 % can identify characteristics of type 2 inflammation (evidence level 2b; recommendation strength B; 30 voting experts, approval rate 100 %). Recommendation 3.2: FeNO is a potential biomarker for the clinical assessment of type 2 inflammation in COPD. A FeNO50 ≥20 ppb, in combination with other biomarkers, can assist in identifying features of type 2 inflammation (evidence level 2b; recommendation strength B; 30 voting experts, approval rate 100 %). Recommendation 3.2: FeNO is a potential biomarker for the clinical assessment of type 2 inflammation in COPD. A FeNO50 ≥20 ppb, in combination with other biomarkers, can assist in identifying features of type 2 inflammation (evidence level 2b; recommendation strength B; 30 voting experts, approval rate 100 %). Recommendation 3.3: IgE may serve as one of the potential biomarkers for the clinical assessment of type 2 inflammation in COPD patients (evidence level 2b; recommendation strength B; 30 voting experts, approval rate 100 %). Recommendation 3.3: IgE may serve as one of the potential biomarkers for the clinical assessment of type 2 inflammation in COPD patients (evidence level 2b; recommendation strength B; 30 voting experts, approval rate 100 %). Circulating and airway biomarkers are important indicators for identifying type 2 inflammation in patients with COPD. Existing evidence suggests that blood and sputum EOS counts are reliable biomarkers reflecting the status of type 2 inflammation in COPD patients. In addition, FeNO and serum IgE also have certain reference value in the identification of type 2 inflammation in COPD patients.62 Common biomarkers used in the clinical evaluation of type 2 inflammation in COPD patients are summarized in Table 4.Table 4Biomarkers used for clinical assessment of type 2 inflammation in COPD patients.Table 4:BiomarkersReference cut-off values for identifying type 2 inflammation in COPD patientsBlood EOSBlood EOS count ≥300 cells/µL and/or blood EOS percentage ≥ 2 %Sputum EOSSputum EOS percentage ≥ 3 %FeNOFeNO50 ≥20 ppbTotal serum IgEElevated total serum IgEAllergen-specific IgEElevated level of at least one allergen-specific IgECOPD: Chronic obstructive pulmonary disease; EOS: Eosinophils; FeNO: Fractional exhaled nitric oxide; FeNO50: Fractional exhaled nitric oxide at 50 mL/s; IgE: Immunoglobulin E. Table 4Biomarkers used for clinical assessment of type 2 inflammation in COPD patients.Table 4:BiomarkersReference cut-off values for identifying type 2 inflammation in COPD patientsBlood EOSBlood EOS count ≥300 cells/µL and/or blood EOS percentage ≥ 2 %Sputum EOSSputum EOS percentage ≥ 3 %FeNOFeNO50 ≥20 ppbTotal serum IgEElevated total serum IgEAllergen-specific IgEElevated level of at least one allergen-specific IgECOPD: Chronic obstructive pulmonary disease; EOS: Eosinophils; FeNO: Fractional exhaled nitric oxide; FeNO50: Fractional exhaled nitric oxide at 50 mL/s; IgE: Immunoglobulin E. Biomarkers used for clinical assessment of type 2 inflammation in COPD patients. COPD: Chronic obstructive pulmonary disease; EOS: Eosinophils; FeNO: Fractional exhaled nitric oxide; FeNO50: Fractional exhaled nitric oxide at 50 mL/s; IgE: Immunoglobulin E. Blood EOS Patients with COPD who have elevated blood EOS counts are associated with increased pulmonary EOS infiltration and higher levels of type 2 airway inflammation.10 Retrospective studies have confirmed that in COPD populations with elevated blood EOS levels, expression of type 2 inflammation-related genes such as C—C motif chemokine 26 (CCL26) and IL13 is significantly upregulated in sputum and bronchial epithelium samples, and the expression of other genes including periostin (POSTN) and serpin B2 (SERPINB2) also shows an upward trend.63 Currently, there is no universally established cutoff value for elevated blood EOS in COPD, but many studies use a peripheral blood EOS count ≥300 cells/µL as the threshold.10,64 Cohort studies suggest that patients with elevated blood EOS have more severe wheezing symptoms, thicker airway walls, poorer quality of life, and a significantly higher risk of acute exacerbations.65,66 In addition, blood EOS count serves as an important biomarker for predicting the long-term efficacy of ICS treatment in COPD patients.67 It is important to note that blood EOS levels are variable over time and require regular monitoring, as relying on a single test result is insufficient for clinical judgment.68 Sputum EOS Studies have shown that there is a significant correlation between blood and sputum EOS in both percentage and absolute count in patients with COPD.69 Currently, a sputum EOS proportion of ≥3 % is commonly used to define eosinophilia phenotype.64 COPD patients with elevated sputum EOS often present with more severe emphysema, worse lung function, and a higher frequency of acute exacerbations requiring systemic corticosteroid treatment.65,70 These findings suggest that sputum EOS count has clinical value in assessing disease severity and predicting prognosis in COPD patients with type 2 inflammation. FeNO FeNO is a specific molecular biomarker released by airway epithelial cells. Increased levels of type 2 inflammatory cytokines IL-4 and IL-13 can promote the upregulation of inducible nitric oxide synthase (iNOS) expression in epithelial cells, thereby increasing FeNO levels. FeNO reflects the activity of airway type 2 inflammation and serves as a biomarker for evaluating the effectiveness of ICS treatment.71, 72, 73 Studies have shown that persistently elevated FeNO levels (≥20 ppb) during the stable phase of COPD are associated with an increased risk of acute exacerbations.74 Compared to blood EOS count, FeNO has higher predictive accuracy for severe COPD exacerbations, although it shows no significant advantage in predicting moderate exacerbations.75 Other studies have indicated that combining FeNO with blood EOS count can enhance the predictive value for acute exacerbations in COPD patients.76 IgE Among patients with COPD, elevated levels of total serum IgE and allergen-specific IgE may be associated with accelerated decline in lung function and increased blood EOS counts.77 Cohort studies have shown that 31.2 % to 34.2 % of COPD patients have total serum IgE ≥100 IU/mL, and 24.8 % have allergen-specific IgE levels ≥0.35 IU/mL.77 One cohort study found that COPD patients who tested positive for at least one airborne allergen in skin prick tests had a significantly higher risk of acute exacerbations compared to those who tested negative, and the time to exacerbation was positively correlated with total IgE levels.78 These findings suggest that allergen screening may help identify COPD patients with type 2 inflammation. In addition, elevated total serum IgE levels have been linked to increased risk of severe acute exacerbations and all-cause mortality in COPD patients, independent of blood eosinophil count.79 A cohort study revealed that total IgE was elevated in specific COPD subgroups: in men with exacerbation history and in patients with lung function decline. Further analysis showed that patients with elevated total serum IgE were at increased risk of the continuous deterioration in lung function.77 Composite type 2 inflammation biomarkers Although the optimal composite biomarkers for type 2 inflammation in COPD have not been fully established, the presence of atopy (specific IgE positivity to any inhaled antigen) and/or elevated FeNO and/or increased blood eosinophils helps to identify type 2 inflammation characteristics. COPD patients exhibiting multiple biomarkers have a higher incidence of acute exacerbations compared to those without these markers.76 Another retrospective study showed that evaluating airway inflammation in COPD patients by combining type 2 biomarkers such as blood eosinophil count, FeNO, and IgE can predict the response to ICS therapy. More than 40 % of patients tested positive once for at least one type 2 inflammation biomarker. 80 Other biomarkers As typical type 2 inflammatory cytokines, IL-4, IL-13, IL-5 and their receptors, as well as eosinophil chemokines, promote the chemotaxis and extravasation of inflammatory cells to sites of airway injury, aiding in the identification of patients with treatable traits of type 2 inflammation.19,81,82 Additionally, thymus and activation-regulated chemokine (TARC) and periostin have also been confirmed as biomarkers of type 2 inflammation,83,84 though currently there is a lack of evidence for using these biomarkers to guide biologic therapy.Clinical question 4: What is the correlation between type 2 inflammation and clinical outcomes in COPD patients?Recommendation 4.1: COPD patients with type 2 inflammation have an increased risk of acute exacerbations and hospitalizations, faster lung function decline, and more severe respiratory symptoms. Therefore, more importance should be attached to the monitoring and follow-up of patients with type 2 inflammation (evidence level 2b; recommendation strength B; 30 voting experts, approval rate 100 %) Clinical question 4: What is the correlation between type 2 inflammation and clinical outcomes in COPD patients? Clinical question 4: What is the correlation between type 2 inflammation and clinical outcomes in COPD patients? Recommendation 4.1: COPD patients with type 2 inflammation have an increased risk of acute exacerbations and hospitalizations, faster lung function decline, and more severe respiratory symptoms. Therefore, more importance should be attached to the monitoring and follow-up of patients with type 2 inflammation (evidence level 2b; recommendation strength B; 30 voting experts, approval rate 100 %) Recommendation 4.1: COPD patients with type 2 inflammation have an increased risk of acute exacerbations and hospitalizations, faster lung function decline, and more severe respiratory symptoms. Therefore, more importance should be attached to the monitoring and follow-up of patients with type 2 inflammation (evidence level 2b; recommendation strength B; 30 voting experts, approval rate 100 %) Acute exacerbation Exacerbation of chronic obstructive pulmonary disease (ECOPD) is an important factor leading to disease progression and poor prognosis. A prospective cohort study based on the Chinese population showed that compared to COPD patients with blood EOS count <300 cells/µL, patients with blood EOS count ≥300 cells/µL had a significantly higher risk of acute exacerbation.7 Results from the COPDGene and ECLIPSE studies indicated that COPD patients with blood EOS count ≥300 cells/µL had a significantly higher risk of acute exacerbation than patients with blood EOS count <300 cells/µL.85 A prospective multicenter observational trial showed that COPD patients with type 2 inflammation (blood EOS count ≥300 cells/µL and/or FeNO ≥20 ppb) had a significantly increased risk of acute exacerbation.86 Another prospective observational study found that over three follow-up visits, COPD patients with persistent (≥2 times) FeNO ≥20 ppb had a significantly higher risk of acute exacerbation (hazard ratio, 1.579; 95 % CI, 1.049–2.378; P = 0.029).74 Hospitalization A real-world study including 3084 hospitalized ECOPD patients showed that 17 % of patients had elevated blood EOS (≥300 cells/µL), and a 1-year follow-up found that patients with elevated blood EOS had a significantly higher frequency of readmission due to ECOPD.87 Similarly, a Canadian study indicated that COPD patients with blood EOS ≥200 cells/µL and/or ≥2 % had a significantly increased risk of COPD-related hospitalization and all-cause hospitalization within 1 year.70 Clinical studies also showed that COPD patients with sputum EOS ≥1.25 % had a significantly increased risk of hospitalization, and sputum EOS levels correlated more strongly with hospitalization risk than blood EOS levels.65 The above evidence suggests that type 2 inflammation is associated with increased hospitalization risk in COPD patients. Lung function A prospective observational study based on two large UK electronic medical record databases showed that COPD patients with blood EOS ≥350 cells/µL experienced faster lung function decline, and ICS could effectively slow down this decline.8 A prospective cohort study based on the Canadian population indicated that compared to COPD patients with blood EOS count <300 cells/µL, patients with blood EOS count ≥300 cells/µL had approximately twice the rate of decline in FEV1.66 The Copenhagen population cohort study showed that for every increase of 100 cells/µL in blood EOS in COPD patients, the annual FEV1 decline increased by 1.0 mL; and for every 10 ppb increase in FeNO, the annual FEV1 decline increased by 1.5 mL, suggesting a significant correlation between type 2 inflammation levels and the rate of pulmonary function decline.88 Notably, the impact of type 2 inflammation on lung function varies across different stages of COPD; the SPIROMICS cohort study found that in GOLD-D group patients, a decrease in blood EOS (≤100 cells/µL) indicated a more pronounced pulmonary function decline.89 Respiratory symptoms A prospective cohort study based on the Chinese population showed that compared to COPD patients with blood EOS <300 cells/µL, those with blood EOS ≥300 cells/µL had significantly higher proportions of chronic respiratory symptoms including chronic cough (38.6 % vs. 46.8 %), sputum production (46.4 % vs. 57.1 %), and wheezing (17.9 % vs. 24.4 %) (all P < 0.05).7 The SPIROMICS cohort study indicated that compared to COPD patients with blood EOS <200 cells/µL, those with blood EOS ≥200 cells/µL reported a higher frequency of wheezing (P = 0.018).65 A prospective observational study showed that upper airway symptoms (UAS) scores and COPD Assessment Test (CAT) scores increased with elevated blood EOS levels in COPD patients.90 The above evidence suggests that type 2 inflammation is associated with more severe respiratory symptoms in COPD patients. Quality of life The SPIROMICS cohort study showed that compared to COPD patients with blood EOS <200 cells/µL, those with blood EOS ≥200 cells/µL had higher St. George’s Respiratory Questionnaire (SGRQ) scores (P = 0.037).65 The COPDGene cohort study indicated that compared to COPD patients with blood EOS <300 cells/µL, patients with blood EOS ≥300 cells/µL had higher SGRQ scores, whereas the ECLIPSE cohort study showed that compared to COPD patients with blood EOS <300 cells/µL, patients with blood EOS ≥300 cells/µL had lower SGRQ scores; however, the differences were not statistically significant in both studies.85 Mortality The association between blood EOS levels and mortality in COPD patients remains controversial. A prospective study showed that among COPD patients hospitalized for acute exacerbation, those with blood EOS counts <50 cells/µL had longer hospital stays and lower 1-year survival rates compared to those with blood EOS counts >150 cells/µL.91 Consistently, an observational study from Spain indicated that COPD patients with elevated blood EOS (≥300 cells/µL) had lower all-cause mortality over a 2-year follow-up (15.8 % vs. 33.7 %).92 Another cohort study found that COPD patients with blood EOS percentage <2 % and/or blood EOS count <150 cells/µL had a higher risk of death.93 A retrospective observational study showed that compared to COPD patients with blood EOS counts between 200 and 250 cells/µL and ≥300 cells/µL, those with blood EOS counts <100 cells/µL had significantly higher mortality rates.94 However, multiple cohort studies have reported no significant association between blood EOS levels and mortality in COPD patients.95, 96, 97 Part III. Therapeutic intervention to COPD patients with type 2 inflammation Clinical question 5: How effective are ICS in treating COPD with type 2 inflammation?Recommendation 5.1: For stable COPD patients with characteristics of type 2 inflammation, ICS should be considered in combination with long-acting bronchodilators (evidence level 1a; recommendation strength A; 30 voting experts, approval rate 96.7 %). Clinical question 5: How effective are ICS in treating COPD with type 2 inflammation? Clinical question 5: How effective are ICS in treating COPD with type 2 inflammation? Recommendation 5.1: For stable COPD patients with characteristics of type 2 inflammation, ICS should be considered in combination with long-acting bronchodilators (evidence level 1a; recommendation strength A; 30 voting experts, approval rate 96.7 %). Recommendation 5.1: For stable COPD patients with characteristics of type 2 inflammation, ICS should be considered in combination with long-acting bronchodilators (evidence level 1a; recommendation strength A; 30 voting experts, approval rate 96.7 %). Application of ICS in the treatment of type 2 inflammation in COPD ICS-containing therapies can significantly reduce the incidence of acute exacerbations in COPD patients with elevated EOS counts. A post hoc analysis of a randomized, controlled phase III trial (ETHOS) showed that, compared with non-ICS treatment, triple therapy containing ICS significantly reduced the incidence of moderate-to-severe exacerbations in patients with baseline blood EOS counts ≥100 cells/µL, whereas no significant reduction in exacerbation rate was observed in patients with EOS <100 cells/µL.98 Other studies have also demonstrated that ICS significantly reduce the incidence of exacerbations in COPD patients at different blood EOS thresholds, including EOS ≥2 % and EOS >200 cells/µL. Several randomized controlled trials (RCTs) have shown that ICS-containing therapy significantly reduces the incidence of acute exacerbations in COPD patients with blood EOS ≥2 % (P < 0.05), but not in those with blood EOS <2 % (P > 0.05).51,98 The latest meta-analysis has shown that, in patients with blood EOS counts ≥200 cells/µL or ≥2 %, the use of ICS-containing regimens significantly reduces the risk of all-cause mortality; moreover, a blood EOS count ≥200 cells/µL was identified as the best predictor of reduced all-cause mortality following ICS treatment in COPD patients.99 Another meta-analysis revealed that the independent effect of ICS on reducing the risk of acute exacerbations in COPD patients was 20 % when EOS was ≥2 %, 35 % when EOS was ≥150 cells/µL, and 39 % when EOS was ≥300 cells/µL.48 According to GOLD 2025, ICS should be considered in stable COPD patients with elevated blood EOS levels, coexisting asthma, or a history of asthma, in addition to long-acting bronchodilators.10 Long-term use of ICS is associated with an increased risk of active tuberculosis. Therefore, screening for latent tuberculosis infection should be considered prior to initiating long-term ICS therapy. Importantly, ICS is not recommended for patients with confirmed active TB due to its potential to exacerbate the infection through immunosuppression. In patients with a history of TB that has been stabilized, ICS may be considered if there is a high risk of acute exacerbation, but close monitoring of treatment response and imaging findings is required to prevent relapse or worsening of the disease.100 Attention should be paid to potential adverse effects associated with ICS use. Common adverse effects include pneumonia, oral candidiasis, throat irritation, cough, and hoarseness. Rare adverse effects include allergic reactions such as rash, urticaria, angioedema, and bronchospasm. Very rare adverse effects include cataracts, hyperglycemia, mycobacterial infections (including Mycobacterium tuberculosis), Cushing’s syndrome, dyspepsia, and joint pain.101, 102, 103, 104, 105Clinical question 6: What are the therapeutic strategies for biologics targeting type 2 inflammation in COPD?Recommendation 6.1: For COPD patients with type 2 inflammation who continue to experience acute exacerbations despite optimized inhalation therapy, it is recommended to add biologic agents (evidence level 1b; recommendation strength A; 30 voting experts, approval rate 100 %). Clinical question 6: What are the therapeutic strategies for biologics targeting type 2 inflammation in COPD? Clinical question 6: What are the therapeutic strategies for biologics targeting type 2 inflammation in COPD? Recommendation 6.1: For COPD patients with type 2 inflammation who continue to experience acute exacerbations despite optimized inhalation therapy, it is recommended to add biologic agents (evidence level 1b; recommendation strength A; 30 voting experts, approval rate 100 %). Recommendation 6.1: For COPD patients with type 2 inflammation who continue to experience acute exacerbations despite optimized inhalation therapy, it is recommended to add biologic agents (evidence level 1b; recommendation strength A; 30 voting experts, approval rate 100 %). In patients with COPD accompanied by type 2 inflammation, multiple biologic agents targeting type 2 cytokines and epithelial-derived alarmins are currently under investigation (Table 5, Table 6).106Table 5Biologics targeting type 2 inflammation with approved indications or therapeutic prospects in COPD.Table 5:TargetBiologicsStudyCharacteristics of the study populationMain study outcomesSmoking historyPFTHistory of acute exacerbationEOS levelIL-4RαDupilumabBOREAS109(Clinical Phase III Trial)Current or previous smoking (≥10 packs per year)Post-BD FEV1/FVC <0.7;30 % 20 %At least two moderate acute exacerbations or at least one severe acute exacerbation within the previous year–Ongoing, the primary endpoint is the annual incidence rate of acute exacerbationTITANIA125(Clinical Phase III Trial)A smoking history of ≥10 packs per yearPost-BD FEV1/FVC <0.7;FEV1 % pred >20 %At least two moderate acute exacerbations or at least one severe acute exacerbation within the previous year–Ongoing, the primary endpoint is the annual incidence rate of acute exacerbationMIRANDA126(Clinical Phase III Trial)A smoking history of ≥10 packs per yearPost-BD FEV1/FVC <0.7;FEV1 % pred >20 %At least two moderate acute exacerbations or at least one severe acute exacerbation within the previous year–Ongoing, the primary endpoint is the annual incidence rate of acute exacerbationST2AstegolimabCOPD-ST2OP127(Clinical Phase IIa Trial)A smoking history of ≥10 packs per yearPost-BD FEV1/FVC <0.7;FEV1 % pred <80 %At least two moderate to severe acute exacerbations within the previous year–Not significantly reduce the annual incidence of acute exacerbationALIENTO128(Clinical Phase IIb Trial)Current or previous smoking (≥10 packs per year)Post-BD FEV1/FVC <0.7;20 % ≤FEV1 % pred <80 %At least two moderate to severe acute exacerbations within the previous year–Ongoing, the primary endpoint is the annual incidence rate of acute exacerbationARNASA128(Clinical Phase III Trial)Current or previous smoking (≥10 packs per year)Post-BD FEV1/FVC <0.7;20 % ≤FEV1 % pred <80 %At least two moderate to severe acute exacerbations within the previous year–Ongoing, the primary endpoint is the annual incidence rate of acute exacerbationALNASA129(Clinical Phase III Trial)Current or previous smoking (≥10 packs per year)Post-BD FEV1/FVC <0.7;20 % ≤FEV1 % pred <80 %At least two moderate to severe acute exacerbations within the previous year–Ongoing, the primary endpoint is the incidence of adverse eventsTSLPTezepelumabCOURSE130(Clinical Phase IIa Trial)Current or previous smoking (≥10 packs per year)Post-BD FEV1/FVC <0.7;20 % ≤FEV1 % pred <80 %At least two moderate to severe acute exacerbations within the previous yearPatients were stratified into three categories according to blood EOS count during the screening period, including blood EOS <150 cells/µL, 150 cells/µL ≤ blood EOS <300 cells/µL, and blood EOS ≥300 cells/µLNot significantly reduce the annual incidence of acute exacerbationUPTREAM-COPD131(Clinical Phase II Trial)Current or previous smoking (≥10 packs per year)Post-BD FEV1/FVC <0.7;30 % ≤FEV1 % pred <80 %At least one moderate to severe acute exacerbations within the previous year——Ongoing, the primary endpoint is the change in eosinophil count in bronchial mucosal tissue from baseline at week 20JOURNEY132(Clinical Phase III Trial)Current or previous smoking (≥10 packs per year)Post-BD FEV1/FVC <0.7;20 % ≤FEV1 % pred <70 %At least two moderate acute exacerbations or at least one severe acute exacerbation within the previous yearBlood EOS count during the screening period was ≥150 cells/µLOngoing, the primary endpoint is the annual incidence rate of acute exacerbationEMBARK133(Clinical Phase III Trial)Current or previous smoking (≥10 packs per year)Post-BD FEV1/FVC <0.7;20 % ≤FEV1 % pred <70 %At least two moderate acute exacerbations or at least one severe acute exacerbation within the previous yearBlood EOS count during the screening period was ≥150 cells/µLOngoing, the primary endpoint is the annual incidence rate of acute exacerbationBD: Bronchodilator; COPD: Chronic obstructive pulmonary disease; COPDCompEx: COPD composite exacerbation; EOS: Eosinophils; FEV1: Forced expiratory volume in 1 s; FVC: Forced vital capacity; FEV1 % pred: Forced expiratory volume in 1 s percent predicted; IL: Interleukin; PFT: Pulmonary function test; ST2: Suppression of tumorigenicity 2 protein; TSLP: Thymic stromal lymphopoietin. Table 5Biologics targeting type 2 inflammation with approved indications or therapeutic prospects in COPD.Table 5:TargetBiologicsStudyCharacteristics of the study populationMain study outcomesSmoking historyPFTHistory of acute exacerbationEOS levelIL-4RαDupilumabBOREAS109(Clinical Phase III Trial)Current or previous smoking (≥10 packs per year)Post-BD FEV1/FVC <0.7;30 % 20 %At least two moderate acute exacerbations or at least one severe acute exacerbation within the previous year–Ongoing, the primary endpoint is the annual incidence rate of acute exacerbationTITANIA125(Clinical Phase III Trial)A smoking history of ≥10 packs per yearPost-BD FEV1/FVC <0.7;FEV1 % pred >20 %At least two moderate acute exacerbations or at least one severe acute exacerbation within the previous year–Ongoing, the primary endpoint is the annual incidence rate of acute exacerbationMIRANDA126(Clinical Phase III Trial)A smoking history of ≥10 packs per yearPost-BD FEV1/FVC <0.7;FEV1 % pred >20 %At least two moderate acute exacerbations or at least one severe acute exacerbation within the previous year–Ongoing, the primary endpoint is the annual incidence rate of acute exacerbationST2AstegolimabCOPD-ST2OP127(Clinical Phase IIa Trial)A smoking history of ≥10 packs per yearPost-BD FEV1/FVC <0.7;FEV1 % pred <80 %At least two moderate to severe acute exacerbations within the previous year–Not significantly reduce the annual incidence of acute exacerbationALIENTO128(Clinical Phase IIb Trial)Current or previous smoking (≥10 packs per year)Post-BD FEV1/FVC <0.7;20 % ≤FEV1 % pred <80 %At least two moderate to severe acute exacerbations within the previous year–Ongoing, the primary endpoint is the annual incidence rate of acute exacerbationARNASA128(Clinical Phase III Trial)Current or previous smoking (≥10 packs per year)Post-BD FEV1/FVC <0.7;20 % ≤FEV1 % pred <80 %At least two moderate to severe acute exacerbations within the previous year–Ongoing, the primary endpoint is the annual incidence rate of acute exacerbationALNASA129(Clinical Phase III Trial)Current or previous smoking (≥10 packs per year)Post-BD FEV1/FVC <0.7;20 % ≤FEV1 % pred <80 %At least two moderate to severe acute exacerbations within the previous year–Ongoing, the primary endpoint is the incidence of adverse eventsTSLPTezepelumabCOURSE130(Clinical Phase IIa Trial)Current or previous smoking (≥10 packs per year)Post-BD FEV1/FVC <0.7;20 % ≤FEV1 % pred <80 %At least two moderate to severe acute exacerbations within the previous yearPatients were stratified into three categories according to blood EOS count during the screening period, including blood EOS <150 cells/µL, 150 cells/µL ≤ blood EOS <300 cells/µL, and blood EOS ≥300 cells/µLNot significantly reduce the annual incidence of acute exacerbationUPTREAM-COPD131(Clinical Phase II Trial)Current or previous smoking (≥10 packs per year)Post-BD FEV1/FVC <0.7;30 % ≤FEV1 % pred <80 %At least one moderate to severe acute exacerbations within the previous year——Ongoing, the primary endpoint is the change in eosinophil count in bronchial mucosal tissue from baseline at week 20JOURNEY132(Clinical Phase III Trial)Current or previous smoking (≥10 packs per year)Post-BD FEV1/FVC <0.7;20 % ≤FEV1 % pred <70 %At least two moderate acute exacerbations or at least one severe acute exacerbation within the previous yearBlood EOS count during the screening period was ≥150 cells/µLOngoing, the primary endpoint is the annual incidence rate of acute exacerbationEMBARK133(Clinical Phase III Trial)Current or previous smoking (≥10 packs per year)Post-BD FEV1/FVC <0.7;20 % ≤FEV1 % pred <70 %At least two moderate acute exacerbations or at least one severe acute exacerbation within the previous yearBlood EOS count during the screening period was ≥150 cells/µLOngoing, the primary endpoint is the annual incidence rate of acute exacerbationBD: Bronchodilator; COPD: Chronic obstructive pulmonary disease; COPDCompEx: COPD composite exacerbation; EOS: Eosinophils; FEV1: Forced expiratory volume in 1 s; FVC: Forced vital capacity; FEV1 % pred: Forced expiratory volume in 1 s percent predicted; IL: Interleukin; PFT: Pulmonary function test; ST2: Suppression of tumorigenicity 2 protein; TSLP: Thymic stromal lymphopoietin. Biologics targeting alarmins with therapeutic potential in COPD. BD: Bronchodilator; COPD: Chronic obstructive pulmonary disease; COPDCompEx: COPD composite exacerbation; EOS: Eosinophils; FEV1: Forced expiratory volume in 1 s; FVC: Forced vital capacity; FEV1 % pred: Forced expiratory volume in 1 s percent predicted; IL: Interleukin; PFT: Pulmonary function test; ST2: Suppression of tumorigenicity 2 protein; TSLP: Thymic stromal lymphopoietin. Targeted biologics for type 2 inflammation Anti-IL-4Rα monoclonal antibody Interleukin-4 receptor alpha (IL-4Rα) is a shared subunit of the IL-4 and IL-13 receptor complexes. Anti-IL-4Rα therapy simultaneously blocks the signaling pathways of IL-4 and IL-13, which are key and central drivers of type 2 inflammation. This dual inhibition suppresses a series of pathophysiological effects, including goblet cell hyperplasia and mucus hypersecretion, airway remodeling, and alveolar destruction. It represents an effective strategy for broadly suppressing type 2 inflammation.107,108 Currently, two large randomized, double-blind, placebo-controlled phase III clinical trials (BOREAS and NOTUS) have consistently demonstrated that in patients with COPD who continue to experience acute exacerbations despite optimized inhaled therapy and who show characteristics of type 2 inflammation (defined as at least one blood EOS count ≥300 cells/µL during the screening period), treatment with dupilumab for 52 weeks significantly reduced the annual rate of acute exacerbations by 30 % in BOREAS (0.78 vs. 1.10, RR 0.70, P < 0.001,) and 34 % in NOTUS (0.86 vs. 1.30, RR 0.66, P < 0.001) on top of triple therapy. Lung function (pre-bronchodilator [BD] FEV1) improved significantly from baseline by 83 mL in BOREAS (160 mL vs. 77 mL, P < 0.001) and 82 mL in NOTUS (139 mL vs. 57 mL, P < 0.001) at week 12, with benefits sustained through week 52.109,110 Pooled analyses from the two studies showed that patients’ respiratory symptoms (Evaluating Respiratory Symptoms in COPD [E-RS-COPD] score) and health-related quality of life (SGRQ score) significantly improved as early as week 2, with continued benefit throughout the 52-week treatment period.111 In the subgroup of patients with baseline FeNO ≥20 ppb, the benefits of dupilumab were even more pronounced: annual exacerbation rates were reduced by 45 % (0.729 vs. 1.321, RR 0.552, P < 0.0001), and pre-BD FEV1 improved by 131 mL at week 12 and 106 mL at week 52.111 Overall, dupilumab was well tolerated, with adverse event rates comparable to those of placebo.109, 110, 111 Dupilumab has been recommended in the GOLD 2025 guidelines as an escalation treatment for COPD patients who continue to experience acute exacerbations despite triple therapy with ICS+long-acting beta2-adrenoceptor agonist (LABA)+long-acting muscarinic antagonist (LAMA).10 A 7-year U.S. cohort study also showed that, compared to inhaled therapy based on long-acting bronchodilators (LABDs), dupilumab significantly reduced all-cause mortality (HR 0.53, 95 % CI 0.43–0.65, P < 0.001), emergency department visits (HR 0.78, 95 % CI 0.69–0.89, P < 0.001), and the rate of acute exacerbations (HR 0.59, 95 % CI 0.53–0.65, P < 0.001).112 A recent real-world study has also confirmed that 6 months of anti-IL-4Rα monoclonal antibody therapy combined with triple inhaled therapy in patients with type 2 inflammation-related COPD achieved greater improvements in lung function (pre-BD FEV1: 0.52 ± 0.49 L vs. 0.09 ± 0.42 L, P < 0.05; pre-BD forced vital capacity [FVC]: 0.62 ± 0.57 L vs. 0.08 ± 0.64 L, P < 0.05) and symptom relief (CAT score: 3.94 ± 2.97 vs. −1.21 ± 2.64, P < 0.05) compared to conventional triple inhaled therapy.113 Anti-IL-5/5R monoclonal antibodies IL-5 promotes the proliferation, differentiation, activation, and survival of EOS in type 2 inflammatory responses,27 suggesting that IL-5 or its receptor (IL-5R) may serve as potential therapeutic targets in COPD with type 2 inflammation. A randomized, double-blind, placebo-controlled phase III clinical trial (METREX) of the anti-IL-5 monoclonal antibody mepolizumab showed that in eosinophilic COPD patients (defined as EOS ≥150 cells/µL at screening or ≥300 cells/µL at any point in the past year), 52 weeks of mepolizumab treatment reduced the annual rate of acute exacerbations by 18 % (1.40 vs. 1.71, RR = 0.82, P = 0.04); however, no significant benefit was observed in the overall study population.114 In another phase III trial (METREO) targeting eosinophilic COPD patients, neither of the two mepolizumab dosing regimens significantly reduced the annual exacerbation rate over 52 weeks.114 The recently published MATINEE phase III trial, which enrolled COPD patients with more definitive evidence of type 2 inflammation (EOS ≥300 cells/µL at screening and ≥150 cells/µL at any point in the past year or 14–21 days before randomization), found that mepolizumab treatment for up to 104 weeks significantly reduced the annualized rate of moderate-to-severe acute exacerbations compared to placebo (0.80 vs. 1.01, RR = 0.79, P = 0.01), and prolonged the time to first moderate-to-severe acute exacerbation (419 days vs. 321 days, HR = 0.77, P = 0.009).115 However, there were no statistically significant differences between groups in health-related quality of life at 52 weeks (measured by CAT and SGRQ scores), symptom scores (E-RS-COPD), or changes in pre-BD FEV1 from baseline (24.6 mL vs. 33.6 mL). The incidence of adverse events was similar between the mepolizumab and control groups.115 Two randomized, double-blind, placebo-controlled phase III clinical trials (GALATHEA and TERRANOVA) evaluating the anti-IL-5R monoclonal antibody benralizumab demonstrated that among COPD patients with baseline blood EOS counts ≥220 cells/µL, benralizumab treatment at all dose levels failed to reduce the annual rate of acute exacerbations or produce significant improvements in lung function.116 A follow-up phase III trial (RESOLUTE [NCT04053634]) is ongoing,117 aiming to assess the potential clinical benefits of benralizumab in a more precisely defined population with stronger evidence of type 2 inflammation (screening EOS ≥300 cells/µL and ≥150 cells/µL at any time in the past year). Biologics targeting epithelial-derived alarmins Epithelial-derived alarmins (such as IL-33 and TSLP) are closely associated with type 2 inflammation in COPD. They play a critical role in the activation of immune cell populations such as mast cells, EOS, and ILC2, promoting the production of type 2 cytokines and participating in type 2 inflammatory responses in COPD. At the same time, they can also mediate non-type 2 inflammation, representing emerging therapeutic targets in COPD.118 Currently, biologics targeting IL-33 and TSLP are undergoing clinical investigation in COPD patient populations. Anti-IL-33/ST2 monoclonal antibodies IL-33 is an epithelial-derived alarmin that acts as a pro-inflammatory endogenous signaling molecule, and its biological activity is mediated by the interaction of the ST2 receptor and the IL-1 receptor accessory protein.106 A randomized, double-blind, placebo-controlled phase IIa clinical trial (NCT03546907) of the anti-IL-33 monoclonal antibody itepekimab confirmed that, among COPD patients with a history of smoking, itepekimab significantly reduced the rate of moderate-to-severe exacerbations by 42 % compared to placebo (0.89 vs. 1.55, RR = 0.58, P = 0.011), improved FEV1 by 90 mL, and demonstrated a safety profile comparable to that of the placebo group.20 Based on these findings, two phase III trials (AERIFY-1 [NCT04701983] and AFRIFY-2 [NCT04751487]) are being conducted to investigate the benefits of itepekimab in COPD patients with a history of smoking.119,120 Participants who complete the trials will enter an extension phase III trial (AFRIFY-4 [NCT06208306]) to evaluate the long-term efficacy and safety of itepekimab.121 In addition, an exploratory phase II trial of itepekimab (AFRIFY-3 [NCT05326412]) is ongoing to investigate the mechanism of action and its impact on airway inflammation in COPD.122 Another anti-IL-33 monoclonal antibody, tozorakimab, was evaluated in a randomized, double-blind, placebo-controlled phase IIa clinical trial (FRONTIER-4). The results showed that, in COPD patients with a history of ≥1 moderate/severe exacerbation in the past 2 years and coexisting chronic bronchitis, tozorakimab did not significantly improve pre-BD FEV1 at week 12 (19 mL vs. −5 mL, P = 0.216), nor did it delay the time to first COPD composite exacerbation (COPDCompEx). However, numerically greater improvements in lung function were observed in patients with ≥2 exacerbations in the past year and blood eosinophil count ≥150 cells/µL.123 Currently, multiple phase III trials of tozorakimab are underway (OBERON [NCT05166889], TITANIA [NCT05158387], MIRANDA [NCT06040086]) to evaluate its efficacy and safety in COPD patients with a history of smoking and high risk of exacerbations, with results pending publication.124, 125, 126 A randomized, double-blind, placebo-controlled phase IIa clinical trial (COPD-ST2OP) of the anti-ST2 monoclonal antibody astegolimab showed that treatment with astegolimab did not reduce the annual rate of exacerbations in COPD patients with ≥2 moderate-to-severe exacerbations in the past year.127 Astegolimab is also being evaluated in multiple clinical trials, including a phase IIb trial (ALIENTO [NCT05037929]) and two phase III trials (ARNASA [NCT05595642], ALNASA [NCT05878769]), aimed at exploring its efficacy and safety in COPD patients with frequent exacerbations, though no results have been reported yet.128,129 Anti-TSLP monoclonal antibodies TSLP is also an epithelial-derived alarmin that interacts with IL-7Rα and the TSLP receptor and stimulates thymocytes and B-cell lymphopoiesis.106 A randomized, double-blind, placebo-controlled phase IIa clinical trial (COURSE) of the anti-TSLP monoclonal antibody tezepelumab showed that, among COPD patients with ≥2 moderate-to-severe exacerbations in the past year, tezepelumab did not significantly reduce the annual rate of exacerbations (1.75 vs. 2.11, RR = 0.83, P = 0.10 [one-sided]). However, numerically greater benefits were observed in COPD patients with blood eosinophil counts ≥150 cells/µL and ≥300 cells/µL.130 Another randomized, double-blind, placebo-controlled phase II clinical trial of tezepelumab (UPSTREAM-COPD [NCT05507242]) is currently underway to investigate its effects on airway inflammation in COPD patients with a history of smoking.131 Additionally, two phase III clinical trials of tezepelumab in the field of COPD—JOURNEY (NCT06878261)132 and EMBARK (NCT06883305)133—have also been initiated.Clinical question 7: How should the therapeutic response to biologics be assessed in COPD patients with type 2 inflammation?Recommendation 7.1: After initiating biologic therapy in COPD patients with type 2 inflammation, symptoms, lung function, and the occurrence of acute exacerbations should be dynamically assessed (evidence level 1b; recommendation strength A; 30 voting experts, approval rate 100 %).Recommendation 7.2: For COPD patients with type 2 inflammation, it is not recommended to evaluate the therapeutic response to biologics solely based on changes in blood EOS counts (evidence level 1b; recommendation strength A; 30 voting experts, approval rate 100 %).Recommendation 7.3: For COPD patients with type 2 inflammation, adverse reactions related to the biologic agents should be monitored during treatment (evidence level 5; recommendation strength D; 30 voting experts, approval rate 100 %). Clinical question 7: How should the therapeutic response to biologics be assessed in COPD patients with type 2 inflammation? Clinical question 7: How should the therapeutic response to biologics be assessed in COPD patients with type 2 inflammation? Recommendation 7.1: After initiating biologic therapy in COPD patients with type 2 inflammation, symptoms, lung function, and the occurrence of acute exacerbations should be dynamically assessed (evidence level 1b; recommendation strength A; 30 voting experts, approval rate 100 %). Recommendation 7.1: After initiating biologic therapy in COPD patients with type 2 inflammation, symptoms, lung function, and the occurrence of acute exacerbations should be dynamically assessed (evidence level 1b; recommendation strength A; 30 voting experts, approval rate 100 %). Recommendation 7.2: For COPD patients with type 2 inflammation, it is not recommended to evaluate the therapeutic response to biologics solely based on changes in blood EOS counts (evidence level 1b; recommendation strength A; 30 voting experts, approval rate 100 %). Recommendation 7.2: For COPD patients with type 2 inflammation, it is not recommended to evaluate the therapeutic response to biologics solely based on changes in blood EOS counts (evidence level 1b; recommendation strength A; 30 voting experts, approval rate 100 %). Recommendation 7.3: For COPD patients with type 2 inflammation, adverse reactions related to the biologic agents should be monitored during treatment (evidence level 5; recommendation strength D; 30 voting experts, approval rate 100 %). Recommendation 7.3: For COPD patients with type 2 inflammation, adverse reactions related to the biologic agents should be monitored during treatment (evidence level 5; recommendation strength D; 30 voting experts, approval rate 100 %). GOLD 2025 emphasizes that the primary therapeutic goals for COPD are to reduce symptoms and future risk of exacerbations.10 Biologics, as novel targeted therapies with the potential to control airway inflammation in COPD at the mechanistic level and improve clinical outcomes, have been evaluated in multiple randomized, double-blind, placebo-controlled clinical trials. These studies evaluated the impact of biologics on symptom control, quality of life, lung function, and acute exacerbations, and performed exploratory analyses of changes in type 2 inflammation biomarkers such as blood EOS counts and FeNO.106 Changes of blood EOS and FeNO may correspond to the level of controlling type 2 airway inflammation.134,135 Symptom control As persistent dyspnea, chronic cough, sputum production, chest tightness, and wheezing are the main symptoms in patients with COPD, symptom control is also one of the key therapeutic goals in COPD.136 In clinical trials of biologics, symptom scores, such as E-RS-COPD score, modified Medical Research Council Dyspnea Scale (mMRC), and CAT score are commonly used as secondary endpoints, requiring a typical observational duration of at least 3 months.135 Among existing phase II/III clinical studies of biologics for COPD, only dupilumab, an anti-IL-4Rα agent, has demonstrated significant benefit in respiratory symptoms. A significant improvement in E-RS-COPD symptom scores was observed as early as week 2 of treatment in COPD patients with type 2 inflammation.137 At week 52, the total E-RS-COPD score showed a significant improvement from baseline by 2.5 points (vs. placebo least squares mean difference [LSMD] −0.9, P = 0.0006), with a higher proportion of treatment responders (defined as ≥2-point improvement from baseline) in the dupilumab group (38.4 % vs. 30.6 %, P = 0.0007). Individual scores for dyspnea, cough and sputum, and chest symptoms all showed significant benefit.137 In the METREX and METRO trials, the stratified meta-analysis of patients with eosinophilic COPD demonstrated a greater improvement in CAT scores from baseline compared to placebo (−0.9, P = 0.039), and a higher responder rate (39 % vs. 33 %, OR 1.39, P = 0.024) after 52 week-treatment of mepolizumab (anti-IL-5).114 However, the MATINEE trial showed no significant differences in CAT or E-RS-COPD scores between the mepolizumab and placebo groups.115 The anti-IL-5R agent (benralizumab) did not show significant improvement in symptom scores in phase III clinical trials for COPD.116 Improvement in quality of life Quality of life is an important indicator for assessing the progression of chronic diseases. Evaluating quality of life not only helps determine the efficacy of biologic therapies but also facilitates early identification of high-risk populations with psychological or behavioral issues.138 Commonly used assessment tools include SGRQ, EuroQol-5 Dimension (EQ-5D) questionnaire, and Visual Analog Scale (VAS), with a typical observation period of at least 3 months.135 Among the existing phase II/III clinical trials of biologics for COPD, only the anti-IL-4Rα agent dupilumab has demonstrated significant improvement in quality of life. A significant improvement in SGRQ scores was observed as early as week 4 of treatment in COPD patients with type 2 inflammation.137 At week 52, the total SGRQ score improved significantly from baseline by 10.0 points (vs. placebo LSMD −3.4, P < 0.0001), with a higher proportion of treatment responders (defined as ≥4-point improvement from baseline) in the dupilumab group (51.4 % vs. 44.6 %, P = 0.0089). Significant benefits were observed in the symptoms, activity, and impact domains of the questionnaire.137 In phase III trials of anti-IL-5 mepolizumab and anti-IL-5R benralizumab in COPD, no significant differences in SGRQ scores were found compared to placebo.115,116,139 A subgroup meta-analysis of patients with eosinophilic phenotype from the METREX and METRO trials indicated that mepolizumab treatment led to improved quality of life at 12 and 24 weeks compared to placebo; however, these benefits did not persist through week 52.114 Similarly, in the MATINEE study, no significant differences in SGRQ score improvements were observed between the mepolizumab and placebo groups at week 52.115 No significant improvement in quality of life was observed with benralizumab in phase III COPD studies.116 Improvement in lung function Lung function indices are primarily used to evaluate airflow limitation in patients with COPD, with FEV1 commonly serving as the primary spirometric parameter. In clinical trials, the observation period for assessing improvements in airflow limitation during the stable phase is typically at least 8–12 weeks, while for evaluating maintenance of efficacy, the observation period is usually at least 6 months.135 In two phase III clinical trials of the anti-IL-4Rα monoclonal antibody, a significant improvement in FEV1 was observed as early as week 2 of treatment. At weeks 12 and 52, the pre-bronchodilator FEV1 improvement was on average 62 to 83 mL greater than placebo, confirming that dupilumab can further improve airflow limitation in COPD patients on background triple therapy.109,110,135 In the recently published MATINEE study, no significant improvements in lung function were observed.115 Similarly, no significant improvements in lung function were seen with the anti-IL-5R antibody benralizumab in two previous phase III studies.116 Another ongoing phase III trial of benralizumab is currently underway for further evaluation.117 Reduction of acute exacerbations As another primary therapeutic goal in COPD management, reducing the frequency of acute exacerbations is currently a key endpoint in evaluating the clinical efficacy of most biologic therapies, with observation periods typically exceeding 1 year.135 Pooled analysis of two phase III trials of the anti-IL-4Rα monoclonal antibody dupilumab demonstrated a significant 31 % reduction in the annual rate of moderate-to-severe acute exacerbations during 52 weeks of treatment in COPD patients with type 2 inflammation (30 % in BOREAS and 34 % in NOTUS).109,110 Recent phase III results also showed that treatment with the anti-IL-5 monoclonal antibody mepolizumab for 52–104 weeks significantly reduced the annual rate of moderate-to-severe acute exacerbations by 21 % in COPD patients with type 2 inflammation (0.80 vs. 1.01, P = 0.01).115 Anti-IL-5R, anti-IL-33, and anti-TSLP monoclonal antibodies have also used the annual rate of acute exacerbations as a primary efficacy endpoint in their respective phase III trials.20,115, 116, 117,123,124,130,139 Type 2 inflammation biomarkers Some clinical trials of biologic agents have conducted exploratory analyses on changes in type 2 inflammation biomarkers such as blood EOS counts and FeNO levels during treatment in COPD patients,109,110,115,116,127,130 and whether specific interventions are required.135 In the BOREAS trial of anti-IL-4Rα monoclonal antibody dupilumab, greater reductions from baseline were observed at week 52 in FeNO, serum eotaxin-3, total serum IgE, and pulmonary and activation-regulated chemokine (PARC) in the dupilumab group compared with placebo. However, changes in blood EOS counts and fibrinogen levels showed no notable differences between groups.109 Similar results were observed in the NOTUS trial. The dupilumab group demonstrated greater reductions in FeNO and total serum IgE at week 52 compared to placebo, while changes in blood EOS counts and fibrinogen levels remained comparable.110 On the other hand, treatment with anti-IL-5/5R monoclonal antibodies led to a marked reduction in blood EOS counts within 4 weeks, with sustained suppression throughout the 52–56 week treatment period.115,116 These findings suggest that different inflammatory biomarkers may have varied clinical significance in assessing the effectiveness of biologics in controlling type 2 airway inflammation in COPD. Blood EOS counts may be more valuable for identifying type 2 inflammation in COPD patients; however, their correlation with the clinical efficacy of biologic therapy appears to be limited.140 Safety of biologic targeted therapies Current clinical evidence indicates that biologics targeting type 2 inflammation are overall well tolerated, with adverse event (AE) rates comparable to those of the placebo group. Most AEs are mild to moderate in severity and transient in nature. The majority of safety data for dupilumab and mepolizumab originate from studies in atopic dermatitis and asthma.141,142 The most commonly reported adverse effects of dupilumab include injection site reactions (such as erythema, pain, and swelling), nasopharyngitis, upper respiratory tract infections, conjunctivitis, arthralgia, and eosinophilia. In the BOREAS and NOTUS studies, adverse events observed in COPD patients with type 2 inflammation treated with dupilumab included headache, hypertension, diarrhea, and back pain. Post hoc analyses of these studies found that peripheral blood eosinophil levels remained stable throughout dupilumab treatment in COPD patients.143 Common adverse events reported with mepolizumab include headache, nasopharyngitis, and injection site reactions. In phase III trials of mepolizumab for COPD patients with type 2 inflammation, the MATINEE study provided follow-up data for up to 104 weeks, showing that overall adverse event rates were also comparable to placebo.115Clinical question 8: How should biologic treatment be provided for patients with COPD and type 2 inflammation who also have comorbid conditions?Recommendation 8.1: For COPD patients with type 2 inflammation accompanied by other type 2 inflammatory diseases such as asthma or atopic dermatitis, it is recommended to initiate biologic therapy in accordance with relevant clinical guidelines (evidence level 4; recommendation strength C; 30 voting experts, approval rate 100 %). Clinical question 8: How should biologic treatment be provided for patients with COPD and type 2 inflammation who also have comorbid conditions? Clinical question 8: How should biologic treatment be provided for patients with COPD and type 2 inflammation who also have comorbid conditions? Recommendation 8.1: For COPD patients with type 2 inflammation accompanied by other type 2 inflammatory diseases such as asthma or atopic dermatitis, it is recommended to initiate biologic therapy in accordance with relevant clinical guidelines (evidence level 4; recommendation strength C; 30 voting experts, approval rate 100 %). Recommendation 8.1: For COPD patients with type 2 inflammation accompanied by other type 2 inflammatory diseases such as asthma or atopic dermatitis, it is recommended to initiate biologic therapy in accordance with relevant clinical guidelines (evidence level 4; recommendation strength C; 30 voting experts, approval rate 100 %). COPD patients frequently have comorbid conditions such as asthma, cardiovascular diseases, metabolic syndrome, osteoporosis, depression, and anxiety.144,145 These comorbidities can be categorized into type 2 inflammatory and non-type 2 inflammatory diseases based on underlying mechanisms. Type 2 inflammatory diseases A systematic review and meta-analysis reported that asthma is the most common comorbidity among patients with COPD and type 2 inflammation, with a prevalence ranging from 14.7 % to 32.5 %.146 A cross-sectional study conducted in China also found that 9.9 % of patients with COPD had comorbid asthma.147 Other type 2 inflammatory diseases that may coexist with COPD include allergic rhinitis (58 %), food allergies (2.7 %), and chronic rhinosinusitis with nasal polyps (0.9 %).148,149 Another cross-sectional study showed a significant association between COPD and atopic dermatitis.150 Type 2 inflammatory diseases are characterized by type 2 inflammation at the affected sites.151 When barrier functions are compromised in the skin, respiratory tract, and gastrointestinal tract, allergens get access to the body and stimulate Th2 cells and ILC2 to secrete type 2 cytokines. These cytokines promote the activation, proliferation, or recruitment of effector immune cells, thereby exacerbating the inflammatory response. Th2 cells can also circulate through the bloodstream to the nose, lungs, and gastrointestinal tract, participating in the pathophysiological processes of various type 2 inflammatory diseases.152,153 Evidence regarding treatment strategies for patients with COPD complicated by both type 2 inflammation and other type 2 inflammatory diseases is currently limited. For patients with COPD and comorbid asthma accompanied by type 2 inflammation, both GOLD 2025 and Global Initiative for Asthma (GINA) 2025 guidelines recommend that treatment plans be developed in accordance with asthma management principles.10,154 The therapy of ICS/LABA or ICS/LABA/LAMA may be optional, while monotherapy with LABA or LAMA alone is not recommended.154 For patients with type 2 asthma who remain uncontrolled despite medium to high doses of ICS, GINA 2025 further recommends the add-on treatment of biologics targeting type 2 cytokines, such as anti-IL-4Rα antibodies, anti–IL-5/IL-5R antibodies, and anti-TSLP antibodies.154 These recommendations suggest that biologics may be a promising therapeutic option for patients with COPD and comorbid type 2 asthma.71 In a case series, three patients with COPD, asthma, and type 2 inflammation who received anti-IL-4Rα antibody therapy showed improvement in asthma- and COPD-related outcomes, including respiratory symptoms, lung function, and FeNO levels, though blood eosinophil counts were unaffected. This suggests that dupilumab may be an effective option for patients with COPD and asthma accompanied by type 2 inflammation.155 A study involving 20 patients with COPD and comorbid asthma characterized by type 2 inflammation also demonstrated that biologic treatment led to significant reductions in acute exacerbation rates, and improvements in respiratory symptoms and lung function compared to baseline.156 Currently, there are no specific pharmacological treatment recommendations for patients with type 2 inflammatory COPD who also have comorbid allergic rhinitis, food allergies, or chronic rhinosinusitis with nasal polyps. For COPD patients presenting with type 2 inflammatory features and comorbid atopic dermatitis, the GOLD guidelines provide no clear treatment recommendations.10 However, both the Expert Consensus on Stratified and Individualized Systemic Therapy for Moderate-to-Severe Atopic Dermatitis (2024 edition) and the Joint Guidelines of the American Academy of Allergy, Asthma & Immunology for Atopic Dermatitis recommend the use of topical therapies combined with anti-IL-4Rα antibodies for maintenance therapy when necessary.157,158 Further research is needed to confirm the potential benefits of biologics in patients with COPD and type 2 inflammation who also have other type 2 inflammatory diseases, thereby providing robust evidence-based support for rational clinical decision-making. Non-type 2 inflammatory comorbidities COPD is often accompanied by other non-type 2 inflammatory comorbidities.144 A systematic review and meta-analysis showed that the most common non-type 2 inflammatory comorbidities in COPD patients are hypertension (17.0–64.7 %), coronary artery disease (19.9–47.8 %), diabetes mellitus (10.2–45.0 %), osteoarthritis (18.0–43.8 %), and mental disorders (12.1–33.0 %).146 In a cross-sectional study conducted in China, the most frequent non-type 2 inflammatory comorbidities were hypertension (17.8 %), bronchiectasis (8.2 %), diabetes mellitus (8.2 %), and coronary artery disease (7.7 %).147 For COPD patients with non-type 2 inflammatory comorbidities, the GOLD 2025 report and the Chronic Obstructive Pulmonary Disease Management Guidelines (2021 revision) emphasize that COPD should be treated according to standard protocols without altering the treatment strategy, while comorbidities should be managed according to the respective specialty guidelines.10,159 A 7-year cohort study demonstrated that treatment with anti-IL-4Rα monoclonal antibody in COPD patients significantly reduced the incidence of related comorbidities, including pneumonia, heart failure, and anxiety.112 Furthermore, in two phase III trials of anti-IL-4Rα treatment for type 2 inflammatory COPD, 34 patients who were not suitable for ICS and received LABA+LAMA background therapy were included and also showed benefit.109,110 This suggests that for COPD patients with type 2 inflammation who are unsuitable for ICS use (e.g., due to severe pneumonia, pulmonary tuberculosis, infections, or ICS allergy),160 add-on anti-IL-4Rα therapy may be recommended after comprehensive assessment, if LABA+LAMA is inadequate for disease control. Comorbidities are prevalent in patients with COPD. Therefore, when adding biologic therapy, special attention should be given to the potential risk of drug–drug interactions between the biologics and medications for comorbid conditions. A clinical study in patients with moderate-to-severe atopic dermatitis revealed that dupilumab had no significant effect on the pharmacokinetic parameters of representative drugs metabolized by major cytochrome P (CYP) 450 enzyme subtypes (including CYP3A4, CYP2C19, CYP2C9, CYP1A2, and CYP2D6), such as midazolam, omeprazole, warfarin, caffeine, and metoprolol.161 However, current evidence from evidence-based data regarding drug interactions between biologics and concomitant medications in COPD patients is very limited. Therefore, potential adverse reactions related to concomitant medications should be closely monitored during treatment to further optimize medication guidelines. Overall, the diagnosis and treatment flowchart of type 2 inflammation in COPD is illustrated in Fig. 2.Fig. 2Diagnosis and treatment flowchart of type 2 inflammation in COPD. COPD: Chronic obstructive pulmonary disease; EOS: Eosinophils; FeNO50: Fractional exhaled nitric oxide at 50 mL/s; GOLD: Global initiative for chronic obstructive lung disease; ICS: Inhaled corticosteroids; PDE: Phosphodiesterase; PFT: Pulmonary function test.Fig. 2 Diagnosis and treatment flowchart of type 2 inflammation in COPD. COPD: Chronic obstructive pulmonary disease; EOS: Eosinophils; FeNO50: Fractional exhaled nitric oxide at 50 mL/s; GOLD: Global initiative for chronic obstructive lung disease; ICS: Inhaled corticosteroids; PDE: Phosphodiesterase; PFT: Pulmonary function test. Future directions COPD is an inflammatory disease with diverse endotypes and phenotypes. Type 2 inflammation has attracted significant attention due to its potential as a target for biologic therapies. However, there remain gaps between the mechanisms and treatment strategies for COPD patients with type 2 inflammation. The following aspects require further research support. Mechanisms of type 2 inflammatory pathways The intrinsic mechanisms of type 2 inflammatory pathways still require further elucidation. Although numerous studies have confirmed the important roles of cytokines in COPD,162,163 their precise functions remain not fully understood. For example, how these cytokines specifically regulate eosinophil infiltration, mucus hypersecretion, and airway remodeling needs more in-depth investigation. On the other hand, the interactions between type 2 inflammation and other inflammatory pathways are worth exploring. The crosstalk between type 2 inflammation, neutrophilic inflammation, and type 1 inflammation may jointly influence COPD progression. For instance, IL-13 may promote neutrophil recruitment by upregulating chemokines, and Th1/Th2 imbalance may exacerbate airway hyperresponsiveness.164 Clarifying these intrinsic or interactive mechanisms will help optimize therapeutic strategies, potentially guide combined biologic treatments, and improve the precise application of existing biologics. Although there are significant differences among the inflammatory endotypes in COPD patients, these endotypes may change over time due to factors such as environmental exposure, infections, and comorbidities.165,166 Future research should focus on identifying these influencing factors, including smoking history, exposure to air pollution, and microbial colonization. Prospective studies are needed to evaluate how inflammatory endotypes evolve and how this evolution affects disease progression and therapeutic responses. This could eventually enable the dynamic adjustment of individualized treatment plans. Potential biomarkers Reliable biomarkers are essential for identifying COPD patients with type 2 inflammation and for evaluating treatment efficacy. EOS is currently the most widely used type 2 inflammation biomarker in researches. However, studies have employed varying thresholds to define elevated EOS levels, and EOS levels in COPD patients tend to fluctuate throughout the disease course. These factors may affect the diagnosis of type 2 inflammation and the evaluation of treatment response. In addition, other type 2 inflammation biomarkers, such as FeNO, serum eotaxin-3, total serum IgE, and PARC, have been shown to significantly decrease from baseline levels in prospective COPD treatment studies. However, the diagnostic thresholds and clinical reliability of these biomarkers still require further clarification and validation.167,168 Future studies should utilize omics technologies and other innovative approaches to explore combinations of multiple biomarkers, which may enhance the accuracy of both diagnosis and treatment evaluation of type 2 inflammation. Target patient populations Identifying the optimal target population for type 2-targeted biologic therapies is a key area of investigation in COPD. Research should focus on clinical and molecular features that may predict therapeutic response, such as frequent exacerbations, elevated eosinophil levels, or comorbid conditions like asthma or allergic rhinitis. Post hoc subgroup analyses from clinical trials may further inform which subpopulations are most likely to benefit from these therapies.169,170 Certain special subgroups, such as elderly patients or those with severe comorbidities, may respond differently to biologic agents.171,172 Future studies should evaluate the safety and efficacy of biologics in these populations, as well as their potential interactions with existing therapies, such as ICS or bronchodilators. Timing of biologic therapy initiation The GOLD 2025 has, for the first time, incorporated biologic therapies into recommendations, but specifically reserved for COPD patients with type 2 inflammation who still experience frequent exacerbations despite follow-up care.10 Further studies are needed to evaluate the feasibility of initiating biologics earlier. In COPD patients with type 2 inflammation who are either unsuitable for ICS or at risk of ICS-related side effects, earlier use of biologics may help reduce the occurrence of such adverse effects. Furthermore, whether using biologics during the initial treatment phase, rather than following a traditional stepwise approach, offers superior clinical benefit remains to be determined. Head-to-head comparisons via multicenter randomized controlled trials are needed to provide solid evidence for optimizing clinical decision-making. Type 2 inflammation should also be assessed during acute exacerbations.173 Prospective RCTs have shown that in patients with asthma or COPD exacerbations and peripheral blood eosinophil counts ≥300 cells/µL, anti-IL-5R monoclonal antibodies are more effective than corticosteroid treatment alone.174 Case series from Chinese patient populations have also reported favorable outcomes using anti-IL-4Rα monoclonal antibodies in eosinophilic COPD with severe exacerbations.175 Whether biologics can be proactively used during eosinophilic exacerbations, especially in the acute phase, remains a promising area for future clinical research. Duration of biologic therapy and long-term outcomes The optimal duration of biologic therapy and its long-term effects on COPD progression, exacerbation rates, and quality of life remain unclear. Currently, the longest continuous use of biologics in RCT studies with COPD approaches 2 years.115 However, further research is needed to determine whether biologic maintenance is necessary, how and when to discontinue treatment, and whether re-initiation of biologics is feasible or beneficial. In addition, longitudinal studies are essential to assess whether targeting type 2 inflammation can alter the course of the disease, reduce mortality, or prevent complications such as cardiovascular events. With the progress of global population aging, the number of COPD patients with multiple comorbidities is increasing. These patients often require treatment for multiple diseases, and it is crucial to evaluate potential interactions or contraindications between biologics and concomitant medications, especially with other monoclonal antibodies or emerging immunotherapies. Summary Future research about type 2 inflammation and biologics in COPD should focus on elucidating the underlying mechanisms, identifying predictive biomarkers, defining target patient populations, and evaluating long-term outcomes. These efforts will lay the foundation for improving the prognosis of COPD patients with type 2 inflammation and for advancing personalized treatment strategies. By addressing these key areas, we can enhance our understanding of COPD heterogeneity and optimize the clinical application of biologic therapies. Funding This work was supported by National Key Research and Development Program of China (Nos. 2022YFF0710800, 2022YFF0710802), Noncommunicable Chronic Diseases-National Science and Technology Major Project (Nos. 2023ZD0506000, 2024ZD0529802, 2023ZD0516400), CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2021-I2M-1-049), National Clinical Key Specialty Major Scientific Research Project (No. Z2023164), and Major Project of the China Medical and Health Development Foundation's Basic Level Respiratory Clinical Research Funding Project. (No. BJ2024JCHX002). CRediT authorship contribution statement Yan Chen: Writing – original draft, Validation, Resources, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization. Ting Yang: Writing – review & editing, Resources, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization. Jing Zhang: Writing – original draft, Validation, Investigation, Conceptualization. Xiangqi Chen: Writing – original draft, Investigation. Xin Chen: Writing – original draft, Investigation. Zhe Cheng: Writing – original draft, Investigation. Yaqing Li: Writing – original draft, Investigation. Xiaoyun Fan: Writing – original draft, Investigation. Wei Han: Writing – original draft, Investigation. Zhiyi He: Writing – original draft, Investigation. Dedong Ma: Writing – original draft, Investigation. Ying Meng: Writing – original draft, Investigation. Junxia Yan: Supervision, Methodology, Investigation, Formal analysis, Data curation. Yan Yin: Writing – original draft, Investigation. Huihui Zeng: Writing – original draft, Project administration, Investigation. Qiong Zhou: Writing – original draft, Investigation. Xiaoming Zhou: Writing – original draft, Investigation. Hui Cai: Writing – original draft, Validation, Project administration, Investigation, Data curation. Yanan Cui: Writing – original draft, Software, Project administration, Investigation, Data curation. Yiming Ma: Writing – original draft, Visualization, Validation, Supervision, Software, Project administration, Investigation, Funding acquisition, Data curation. Fuqiang Wen: Writing – review & editing, Supervision, Investigation. Yongchang Sun: Writing – review & editing, Supervision, Investigation. Dejun Sun: Writing – review & editing, Investigation. Xiaoju Liu: Writing – review & editing, Investigation. Jinping Zheng: Writing – review & editing, Investigation. Wei Wang: Writing – review & editing, Supervision, Investigation. Zeguang Zheng: Writing – review & editing, Investigation. Xixin Yan: Writing – review & editing, Investigation. Shaoxi Cai: Writing – review & editing, Investigation. Jie Cao: Writing – review & editing, Investigation. Yuanlin Song: Writing – review & editing, Investigation. Jianping Zhao: Writing – review & editing, Investigation. Yumin Zhou: Writing – review & editing, Investigation. Huili Zhu: Writing – review & editing, Investigation. Manxiang Li: Writing – review & editing, Investigation. Yanfei Guo: Writing – review & editing, Investigation. Qianli Ma: Writing – review & editing, Investigation. Zhenyu Liang: Writing – review & editing, Investigation. Li Zhao: Writing – review & editing, Investigation. Yahong Chen: Writing – review & editing, Investigation. Jianmiao Wang: Writing – review & editing, Investigation. Fengyan Wang: Writing – review & editing, Investigation. Yuqiong Yang: Writing – review & editing, Investigation. Huajing Yang: Writing – review & editing, Investigation. Jian Kang: Writing – review & editing, Supervision, Resources, Project administration, Investigation, Data curation, Conceptualization. Rongchang Chen: Writing – review & editing, Validation, Supervision, Resources, Project administration, Investigation, Funding acquisition, Data curation, Conceptualization. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.